The monoclonal antibody therapy market is rapidly expanding with all major pharmaceutical companies seeking approval of more antibody drug modalities each year. In addition, many of the blockbuster monoclonal therapeutics are nearing the end of their patents and the opportunity for biosimilars looms in the marketplace.
